Article · 28 Jun 2025
Research articlePublished 2017
1,8-cineole: An Underappreciated Anti-inflammatory Therapeutic
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The inflammatory response is typically initiated by infection or cellular injury, and provides host protection aimed at clearing the initial triggering event, as well as providing long-term protective immunity. When properly functioning, the inflammatory process is a mediator of acute injury to restore tissue health and is characteristically self-limiting once tissue repair and homeostasis have been restored. If tissue health is not restored, such as if the tissue harbors a continuous low grade inflammatory stimulant, then the inflammatory process becomes a chronic response that continuously damages the surrounding tissue in its attempt to provide repair. Left unchecked, long-term inflammation can result in diseases of chronic inflammation, such as autoimmunity or age-related diseases. Choice of current anti-inflammatory therapies is often limited by patient risk-benefit considerations. Traditional approaches to manage chronic inflammation include non-steroidal anti-inflammatory drugs or corticosteroids which provide short-term benefits, but are often plagued with significant side effects that preclude their use for long-term therapy. The newest classes of anti-inflammatory therapeutics, biologics, are engineered monoclonal antibodies that bind pro-inflammatory mediators and neutralize their effects by preventing pro-inflammatory signaling. Unfortunately, biologic therapies are often prohibitively expensive and have serious, sometimes life-threatening side effects. In lieu of biologics or chemically synthesized small molecules, natural products have provided a rich source of small molecule effectors. One particular natural product, 1,8-cineole, also called eucalyptol, is reported to have anti-inflammatory, anti-microbial, and anti-oxidant activity. Several clinical trials have established potent anti-inflammatory activity for 1,8-cineole, which may suggest its use as a primary treatment, or at the very least, an adjunct therapy for current anti-inflammatory agents. We argue that use of 1,8-cineole as an anti-inflammatory agent needs greater study in other diseases with a chronic inflammatory component, including atherosclerotic cardiovascular disease, type 2 diabetes mellitus, and arthritic complications.
Keywords
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Biomolecular Research & Therapeutics.
Article · 28 Jun 2025
Biomarkers in Early Detection and Treatment Monitoring
Article · 28 Jun 2025
Computational Approaches in Drug Discovery and Development
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biomolecular Research & Therapeutics
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Sarah K Brown”
- BylineArticles whose byline prints “William S Garver”
- BylineArticles whose byline prints “Robert A Orlando”
